v3.26.1
12. Stockholders' equity/(deficit)
 12 Months Ended
Feb. 28, 2026
Equity [Abstract]  
12. Stockholders' equity/(deficit) 12.     Stockholders' equity/(deficit)a. Authorized and issued stock by period  

 

Authorized:

 

As of February 28, 2026 the Company had 188,244,452 shares of common stock authorized and available to issue for purposes of satisfying conversion of preferred stock, the exercise and future grant of common stock options, and for purposes of any future business acquisitions and transactions.

 

As of February 28, 2026, Medinotec Inc., the parent Company had 20,000,000 shares of preferred stock authorized and available to issue.

 

Shares outstanding as of February 28, 2025, were 11,733,750. During the second quarter of the fiscal year ended February 28, 2026, the Company issued 10,899 shares of common stock to a retained physician in settlement of research services valued at $54,495 and 10,899 shares to an independent non-executive director as compensation valued at $54,495. The share issue resulted in 11,755,548 shares outstanding as of February 28, 2026. The shares are restricted pursuant to restricted stock agreements and are subject to SEC Rule 144 transfer limitations. No cash consideration was exchanged, and the issuance of these shares had no impact on the Company’s cash position. The fair value of the shares issued has been recognized under operating expenses in the Company’s statement of operations.

 

Issued and outstanding shares

 

   2026  2025
Common shares   11,733,750    11,733,750 
Stock issued   21,798    —   
Total   11,755,548    11,733,750 

 

Share capital:

       
  

2026

$

 

2025

$

Common shares   11,734    11,734 
Stock issued   22    —   
Total   11,756    11,734